C4 Therapeutics, Inc. (CCCC) Dividend History

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted protein degradation therapies for serious diseases, including cancer and rare disorders. Utilizing its proprietary Controlled Covalent Catalysis (C4) platform, the company designs small molecules that selectively bind to and induce the degradation of disease-causing proteins, aiming to create innovative treatments with improved efficacy and safety profiles.

490 Arsenal Way, Watertown, MA, 02472
Phone: (617) 231-0700
Website: https://www.c4therapeutics.com

Dividend History

C4 Therapeutics, Inc. currently does not pay dividends

Company News

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics reported positive data for its multiple myeloma drug candidate cemsidomide, with a 50% overall response rate at the highest dose level. The company is prioritizing the development of cemsidomide and plans to seek partnership opportunities for its BRAF program.

GlobeNewswire Inc.
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight

The BRAF inhibitor market is expected to grow significantly due to the increasing number of cancer patients, rise in biomarker testing, and ongoing research and development of next-generation BRAF-targeting therapies.

GlobeNewswire Inc.

Featured Companies: BDTX PFE
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries

The global NUT midline carcinoma treatment market is expected to grow from $21.88 billion in 2023 to $79.38 billion by 2034, driven by increased investment in cancer research, advances in targeted therapy, and growing awareness of rare cancers. North America and Asia Pacific are expected to be the key growth regions.

GlobeNewswire Inc.

Featured Companies: ABBV AMGN BMY BPMC GILD LLY MRK ZYME
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics presented positive Phase 1 data for its IKZF1/3 degrader cemsidomide in multiple myeloma and non-Hodgkin's lymphoma, demonstrating anti-tumor activity and a well-tolerated safety profile. The company plans to advance cemsidomide into further clinical development.

GlobeNewswire Inc.
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics, Inc. (C4T) has appointed Steve Hoerter, a veteran with over three decades of experience in oncology commercialization, to its Board of Directors. Hoerter's expertise in strategically advancing oncology programs is expected to guide C4T's plans to become a fully integrated biotechnology company.

GlobeNewswire Inc.

Featured Companies: AGIO ORIC

Dividend data last updated 06/07/2025 01:34:23 UTC